Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions

ANVISA completes inspection at Caplin Steriles' facility at Gummidipoondi

Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Warren Remedies commences commercial production of APIs

Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies

The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Alembic received 6 USFDA approvals during Q2FY24

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets